Overview

Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting

Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
This is a pilot study to assess the safety, pharmacokinetics and effectiveness of PINTA 745 or placebo in treating protein energy wasting (PEW) in patients receiving maintenance hemodialysis (MHD).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Pinta Biotherapeutics